FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer

Cancer Research

Volumn 73, Issue 19, 2013, Pages 5926-5935

  Liu, Rui ^a   Li, Jingyi ^b   Xie, Ke ^c   Zhang, Tao ^b   Lei, Yunlong ^a   Chen, Yi ^a   Zhang, Lu ^a   Huang, Kai ^a   Wang, Kui ^a   Wu, Hong ^a   Wu, Min ^d   Nice, Edouard C ^e   Huang, Canhua ^a   Wei, Yuquan ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

^c SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d UNIVERSITY OF NORTH DAKOTA   (United States)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR ETS 1; WNT PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE; CELL NUCLEUS; COCULTURE; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; STROMA; TUMOR ASSOCIATED FIBROBLAST; UPREGULATION;

APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CADHERINS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LUNG NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEIN C-ETS-1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 84885079983     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4718     Document Type: Article

References (23)

1. Kim J, Takeuchi H, Lam ST, Turner RR, Wang H-J, Kuo C, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005;23:2744-53.
2. Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 2005;5:199-209.
3. Neugebauer JM, Amack JD, Peterson AG, Bisgrove BW, Yost HJ. FGF signalling during embryo development regulates cilia length in diverse epithelia. Nature 2009;458:651-4.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
5. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116-29.
6. Robinson BD, Sica GL, Liu Y-F, Rohan TE, Gertler FB, Condeelis JS, et al. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 2009;15:2433-41.
7. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008;68:918-26.
8. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
9. Umezu T, Ohyashiki K, Kuroda M, Ohyashiki J. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene 2012;32:2747-55.
10. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-53.
11. Xie M-H, Holcomb I, Deuel B, Dowd P, Huang A, Vagts A, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999;11:729-35.
12. Hinsby AM, Olsen JV, Bennett KL, Mann M. Signaling initiated by overexpression of the fibroblast growth factor receptor-1 investigated by mass spectrometry. Mol Cell Proteomics 2003;2:29-36.
13. MacDonald BT, Tamai K, He X. Wnt/b-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
14. Yoshie T, Nishiumi S, Izumi Y, Sakai A, Inoue J, Azuma T, et al. Regulation of the metabolite profile by an APC gene mutation in colorectal cancer. Cancer Sci 2012;103:1010-21.
15. Krejci P, Aklian A, Kaucka M, Sevcikova E, Prochazkova J, Masek JK, et al. Receptor tyrosine kinases activate canonical WNT/β-catenin signaling via MAP kinase/LRP6 pathway and direct β-catenin phosphorylation. PLoS ONE 2012;7:e35826.
16. Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, Holzmann K, et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 2008;7:3408-19.
17. Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S, et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res 2012;72:2768-79.
18. Stamatovic SM, Keep RF, Mostarica-Stojkovic M, Andjelkovic AV. CCL2 regulates angiogenesis via activation of Ets-1 transcription factor. J Immunol 2006;177:2651-61.
19. Yu S, Zheng L, Asa SL, Ezzat S. Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter. Am J Physiol Endocrinol Metab 2002;283:E490-E5.
20. Zhao L, Wang H, Liu C, Liu Y, Wang X, Wang S, et al. Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1. Gut 2010;59:1226-35.
21. Roh H, Green DW, Boswell CB, Pippin JA, Drebin JA. Suppression of b-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res 2001;61:6563-8.
22. Qian B-Z, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475:222-5.
23. McCarty MF, Somcio RJ, Stoeltzing O, Wey J, Fan F, Liu W, et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 2007;117:2114-22.